TipRanks
Editas Medicine Inc (CH:8EM)
:8EM
Switzerland Market
8EM
Editas Medicine
RESEARCH TOOLSreports

Editas Medicine (8EM) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

8EM Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
4 Buy
1 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Editas
Medicine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

8EM Stock 12 Month Forecast

Average Price Target

CHF4.71
▲(118.17% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is CHF4.71 with a high forecast of CHF6.56 and a low forecast of CHF3.28. The average price target represents a 118.17% change from the last price of CHF2.16.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"CHF1","4":"CHF4","7":"CHF7","2.5":"CHF2.5","5.5":"CHF5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.55644192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF6.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.71244263,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF4.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.27822096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF3.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.4944955323076927,2.832991064615385,3.171486596923077,3.5099821292307696,3.848477661538462,4.186973193846154,4.525468726153846,4.8639642584615395,5.202459790769231,5.540955323076924,5.879450855384617,6.217946387692308,{"y":6.55644192,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.352649433076923,2.5492988661538463,2.7459482992307693,2.9425977323076924,3.1392471653846155,3.3358965984615385,3.5325460315384616,3.7291954646153846,3.9258448976923077,4.12249433076923,4.319143763846154,4.515793196923077,{"y":4.71244263,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.156,2.2423246892307693,2.3286493784615385,2.4149740676923077,2.501298756923077,2.587623446153846,2.6739481353846157,2.7602728246153845,2.846597513846154,2.932922203076923,3.0192468923076925,3.1055715815384617,3.191896270769231,{"y":3.27822096,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.919,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.919,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.156,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.156,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF6.56Average Price TargetCHF4.71Lowest Price TargetCHF3.28
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ladenburg Thalmann & Co. Analyst forecast on CH:8EM
Rick Bienkowski
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
CHF4.92
Buy
127.65%
Upside
Initiated
08/18/26
Editas Medicine initiated with a Buy at LadenburgEditas Medicine initiated with a Buy at Ladenburg
Bank of America Securities Analyst forecast on CH:8EM
Alec Stranahan
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
08/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Irhythm Technologies (NASDAQ: IRTC) and Editas Medicine (NASDAQ: EDIT)
H.C. Wainwright Analyst forecast on CH:8EM
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF2.46→CHF4.1
Buy
89.71%
Upside
Reiterated
08/06/26
Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)
JonesTrading Analyst forecast on CH:8EM
Boris Peaker
JonesTrading
JonesTrading
CHF6.56
Buy
203.54%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (NYSE: DNA), Exelixis (NASDAQ: EXEL) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on CH:8EM
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/05/26
Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst
RBC Capital Analyst forecast on CH:8EM
Luca Issi
RBC Capital
RBC Capital
CHF3.28
Hold
51.77%
Upside
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Zimmer Biomet Holdings (NYSE: ZBH) and Editas Medicine (NASDAQ: EDIT)
Evercore ISI Analyst forecast on CH:8EM
Jonathan Miller
Evercore ISI
Evercore ISI
CHF12.29
Buy
469.14%
Upside
Reiterated
05/27/26
Editas Medicine preclinical data 'looks highly supportive,' says Evercore ISIEditas Medicine preclinical data 'looks highly supportive,' says Evercore ISI
Chardan Capital Analyst forecast on CH:8EM
Geulah Livshits
Chardan Capital
Chardan Capital
CHF3.28
Buy
51.77%
Upside
Reiterated
05/05/26
Editas Medicine price target raised to $4 from $3.50 at ChardanEditas Medicine price target raised to $4 from $3.50 at Chardan
Truist Financial Analyst forecast on CH:8EM
Joon Lee
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), DocGo (NASDAQ: DCGO) and Editas Medicine (NASDAQ: EDIT)
J.P. Morgan Analyst forecast on CH:8EM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT) and Ascend Wellness Holdings LLC (Other OTC: AAWH)
Wells Fargo Analyst forecast on CH:8EM
Yanan Zhu
Wells Fargo
Wells Fargo
CHF3.28
Hold
51.77%
Upside
Reiterated
03/10/26
Wells Fargo Sticks to Its Hold Rating for Editas Medicine (EDIT)
Clear Street Analyst forecast on CH:8EM
William Maughan
Clear Street
Clear Street
CHF3.77
Buy
74.53%
Upside
Reiterated
03/10/26
Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)
Barclays Analyst forecast on CH:8EM
Gena Wang
Barclays
Barclays
CHF2.46
Hold
13.83%
Upside
Reiterated
11/11/25
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ladenburg Thalmann & Co. Analyst forecast on CH:8EM
Rick Bienkowski
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
CHF4.92
Buy
127.65%
Upside
Initiated
08/18/26
Editas Medicine initiated with a Buy at LadenburgEditas Medicine initiated with a Buy at Ladenburg
Bank of America Securities Analyst forecast on CH:8EM
Alec Stranahan
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
08/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Irhythm Technologies (NASDAQ: IRTC) and Editas Medicine (NASDAQ: EDIT)
H.C. Wainwright Analyst forecast on CH:8EM
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF2.46→CHF4.1
Buy
89.71%
Upside
Reiterated
08/06/26
Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)
JonesTrading Analyst forecast on CH:8EM
Boris Peaker
JonesTrading
JonesTrading
CHF6.56
Buy
203.54%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (NYSE: DNA), Exelixis (NASDAQ: EXEL) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on CH:8EM
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/05/26
Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst
RBC Capital Analyst forecast on CH:8EM
Luca Issi
RBC Capital
RBC Capital
CHF3.28
Hold
51.77%
Upside
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Zimmer Biomet Holdings (NYSE: ZBH) and Editas Medicine (NASDAQ: EDIT)
Evercore ISI Analyst forecast on CH:8EM
Jonathan Miller
Evercore ISI
Evercore ISI
CHF12.29
Buy
469.14%
Upside
Reiterated
05/27/26
Editas Medicine preclinical data 'looks highly supportive,' says Evercore ISIEditas Medicine preclinical data 'looks highly supportive,' says Evercore ISI
Chardan Capital Analyst forecast on CH:8EM
Geulah Livshits
Chardan Capital
Chardan Capital
CHF3.28
Buy
51.77%
Upside
Reiterated
05/05/26
Editas Medicine price target raised to $4 from $3.50 at ChardanEditas Medicine price target raised to $4 from $3.50 at Chardan
Truist Financial Analyst forecast on CH:8EM
Joon Lee
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), DocGo (NASDAQ: DCGO) and Editas Medicine (NASDAQ: EDIT)
J.P. Morgan Analyst forecast on CH:8EM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT) and Ascend Wellness Holdings LLC (Other OTC: AAWH)
Wells Fargo Analyst forecast on CH:8EM
Yanan Zhu
Wells Fargo
Wells Fargo
CHF3.28
Hold
51.77%
Upside
Reiterated
03/10/26
Wells Fargo Sticks to Its Hold Rating for Editas Medicine (EDIT)
Clear Street Analyst forecast on CH:8EM
William Maughan
Clear Street
Clear Street
CHF3.77
Buy
74.53%
Upside
Reiterated
03/10/26
Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)
Barclays Analyst forecast on CH:8EM
Gena Wang
Barclays
Barclays
CHF2.46
Hold
13.83%
Upside
Reiterated
11/11/25
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ZVRAZevra Therapeutics
ELVNEnliven Therapeutics
DFTXDefinium Therapeutics
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Editas Medicine

3 Months
Phil NadeauTD Cowen
Success Rate
7/15 ratings generated profit
47%
Average Return
-3.21%
Copying Phil Nadeau's trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of -3.21% per trade.
1 Year
Phil NadeauTD Cowen
Success Rate
9/15 ratings generated profit
60%
Average Return
+13.91%
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +13.91% per trade.
2 Years
Phil NadeauTD Cowen
Success Rate
8/15 ratings generated profit
53%
Average Return
+13.73%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 53.33% of your transactions generating a profit, with an average return of +13.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8EM Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
8
6
4
3
3
Buy
3
2
2
1
1
Hold
4
1
1
1
1
Sell
2
1
1
1
1
Strong Sell
0
0
0
0
0
total
17
10
8
6
6
In the current month, 8EM has received 4 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. 8EM average Analyst price target in the past 3 months is 4.71.
Each month's total comprises the sum of three months' worth of ratings.

8EM Financial Forecast

8EM Earnings Forecast

Next quarter’s earnings estimate for 8EM is -CHF0.15 with a range of -CHF0.20 to -CHF0.11. The previous quarter’s EPS was -CHF0.12. 8EM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 8EM has Performed in-line its overall industry.
Next quarter’s earnings estimate for 8EM is -CHF0.15 with a range of -CHF0.20 to -CHF0.11. The previous quarter’s EPS was -CHF0.12. 8EM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 8EM has Performed in-line its overall industry.

8EM Sales Forecast

Next quarter’s sales forecast for 8EM is CHF3.64M with a range of CHF405.56K to CHF9.74M. The previous quarter’s sales results were CHF9.64M. 8EM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 8EM has Performed in-line its overall industry.
Next quarter’s sales forecast for 8EM is CHF3.64M with a range of CHF405.56K to CHF9.74M. The previous quarter’s sales results were CHF9.64M. 8EM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 8EM has Performed in-line its overall industry.

8EM Stock Forecast FAQ

What is CH:8EM’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is 4.71.
    What is CH:8EM’s upside potential, based on the analysts’ average price target?
    Editas Medicine Inc has 118.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Editas Medicine Inc a Buy, Sell or Hold?
          Editas Medicine Inc has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Editas Medicine Inc’s share price target?
            The average share price target for Editas Medicine Inc is 4.71. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF6.56 ,and the lowest forecast is CHF3.28. The average share price target represents 118.17% Increase from the current price of CHF2.16.
              What do analysts say about Editas Medicine Inc?
              Editas Medicine Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Editas Medicine Inc?
                To buy shares of CH:8EM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.